Methods For Diagnosing Bipolar Disorders and Attention-Deficit/Hyperactivity Disorder

ABSTRACT

Changes that occur in Na + K +  ATPase regulation and therefore in the membrane potential in cells from bipolar individuals, as compared to cells from unaffected control individuals, are utilized to provide a diagnostic assay for bipolar I and bipolar II disorders. The diagnostic assay may also or instead exploit the similarity of cells from new patients to those of people already known to have bipolar I or bipolar II disorder. A similar diagnostic assay is provided for diagnosing attention-deficit/hyperactivity disorder (ADHD) and unipolar disorder. The diagnostic assays may further involve manipulation of membrane potential by incubation of cells in K + -free buffer and/or incubation with one or more compounds that alter Na + K +  ATPase activity. Although a variety of cells may be used, the diagnostic assays preferably employ lymphoblasts or whole blood cells.

The present application claims priority to U.S. provisional application No. 60/670,237, filed Apr. 12, 2005, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to a method for diagnosing a bipolar disorder, such as bipolar I or bipolar II disorder, and attention-deficit/hyperactivity disorder (ADHD). In particular, this method utilizes changes that occur in Na⁺K⁺ ATPase regulation in cells from bipolar and ADHD individuals, as compared to cells from unaffected control individuals, to provide a diagnostic assay for a bipolar disorder or ADHD. The present invention also relates to a method for diagnosing a bipolar disorder and ADHD through the detection or measurement of such changes.

BACKGROUND OF THE INVENTION

Mental illness afflicts nearly ten percent of the general population both in the United States and in the rest of the world. Bipolar (manic depressive) disorders occur in one to two percent of the population and they are the sixth leading cause of disability (Coryell et al., Am. J. Psychiatry 150:720-727 (1993); Lopez, A. D., and Murray, C. C., Nat. Med. 4:1241-1243 (1998); Hyman, S. E., Am. J. Geriatr. Psychiatry 9:330-339 (2001)). A problem facing the medical community is misdiagnosis of a bipolar disorder. Misdiagnosed patients receive an average of 3.5 misdiagnoses and consult four physicians before receiving an accurate diagnosis (“Living with bipolar disorder: How far have we really come?” National Depressive and Manic-Depressive Association, Chicago, Ill. (2001)).

Attention-deficit/hyperactivity disorder is characterized by persistent inattention and impulsivity. The criteria for this disorder are outlined in DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 2000, American Psychiatric Association, Washington D.C. (2000)). However misdiagnosis and over-diagnosis are common due to a number of barriers including limited access to available mental health services (National Institute of Health. Diagnosis and treatment of attention deficit hyper activity disorder. NIH Consensus Statement, 16(2):1-37 (1998); Foy J. M. and Earls, M. F., Pediatrics 115:97-104 (2005)).

The American Academy of Pediatricians has developed a community consensus for the diagnosis and management of ADHD. Still, there are large discrepancies between practice patterns and the guidelines. There is an urgent need for a simple blood test to identify this illness at an early stage and to treat patients adequately at an early point in time (Benazzi, F., Progress in Neuro-Psycopharmacology and Biological Psychiatry, 29:267-274 (2005)).

The DSM-IV makes a distinction between bipolar I (BPI) and bipolar II (BPII) disorders. Moreover, the symptoms of ADHD are very similar to bipolar I and bipolar II symptoms. In order to better diagnose and treat patients, it can be important to distinguish between these three diseases.

The current diagnostic method for bipolar disorders and ADHD involves a series of clinical interviews and examination using the DSM-IV-TR. However, significant controversy exists about the validity of this manual, which limits the accuracy of clinical diagnosis (Torrey et al, “Surviving Manic Depression”, Basic Books, New York (2002)). In addition, attempts are underway to identify the genes underlying this illness and thereby develop diagnostic markers. However, their identification and possible use as diagnostic markers are years away (Bradbury, J., Lancet 357:1596 (2001)).

According to Benazzi (Benazzi F., Mixed depression: a critical marker of bipolar II disorder, Progress in Neuro-Psycopharmacology and Biological Psychiatry, 29:267-274 (2005)) under-diagnosis and misdiagnosis of BPII are common in clinical practice. In a recent lecture entitled “Bipolar One and Bipolar Two: Will the Real Bipolar Disorder Please Stand Up?”, DePaulo (Fifth Annual Course, Dept. Psychiatry and Behavioral Sciences, Johns Hopkins University, Nov. 6, 2004) highlights the importance of this problem in the diagnosis and treatment in a clinical setting.

Like bipolar disorder, unipolar disorder is also currently diagnosed using the DSM-IV. By definition, unipolar disorder and bipolar disorder are distinct conditions. Unipolar disorder is diagnosed when there has never been a manic episode and at least five of the following symptoms have been present during the same 2 week depressed period:

-   -   Abnormal depressed mood.     -   Abnormal loss of all interest and pleasure.     -   Appetite or weight disturbance, either:         -   Abnormal weight loss (when not dieting) or decrease in             appetite.         -   Abnormal weight gain or increase in appetite.     -   Sleep disturbance, either abnormal insomnia or abnormal         hypersomnia.     -   Activity disturbance, either abnormal agitation or abnormal         slowing (observable by others).     -   Abnormal fatigue or loss of energy.     -   Abnormal self-reproach or inappropriate guilt.     -   Abnormal poor concentration or indecisiveness.     -   Abnormal morbid thoughts of death or suicide.

There is evidence that unipolar disorder is, in part, a genetic disorder. Therefore, as with bipolar disorder, attempts are underway to identify the genes underlying unipolar disorder and thereby develop diagnostic markers. However, this has yet to be achieved.

In virtually every animal cell, the concentration of Na⁺ in the cell (˜12 mM) is lower than the concentration of Na⁺ in the surrounding medium (˜145 mM), and the concentration of K⁺ in the cell (˜140 mM) is higher than the concentration of K⁺ in the surrounding medium (˜4 mM). This imbalance is established and maintained by an active transport system in the plasma membrane. The transporter enzyme Na⁺K⁺ ATPase, also known as the sodium pump, couples breakdown of ATP to the simultaneous movement of both Na⁺ and K⁺ against their electrochemical gradients. For each molecule of ATP hydrolyzed to ADP and P_(i), the Na⁺K⁺ ATPase transports two K⁺ ions inward and three Na⁺ ions outward across the plasma membrane.

The Na⁺K⁺ ATPase is an integral protein with two subunits (Mr ˜50,000 and ˜110,000), both of which span the membrane. A proposed mechanism by which ATP hydrolysis is coupled to ion transport involves the Na⁺K⁺ ATPase cycling between two forms, a phosphorylated form with high affinity for K⁺ and low affinity for Na⁺, and a dephosphorylated form with high affinity for Na⁺ and low affinity for K⁺. The conversion of ATP to ADP and P_(i) occurs in two steps catalyzed by the enzyme.

In addition to the Na⁺K⁺ ATPase, the plasma membrane also contains channel proteins that allow the principal cellular ions (Na⁺, K⁺, Ca²⁺, and Cl⁻) to move through them at different rates down their concentration gradients. Ion concentration gradients generated by pumps and selective movement of ions through channels constitutes the principal mechanism by which a difference in voltage, or electric potential, is generated across the plasma membrane. However, because the plasma membranes of animal cells contain many open K⁺ channels, and relatively few open Na⁺, Ca²⁺, and Cl⁻ channels, the membrane potential in animal cells depends largely on open K⁺ channels. As a result, the major ionic movement across the plasma membrane is that of K⁺ from the inside outward, powered by the K⁺ concentration gradient, leaving an excess of negative charge on the inside and creating an excess of positive charge on the outside.

The magnitude of this membrane potential generally is −50 mV to −70 mV (with the inside of the cell negative relative to the outside), which is characteristic of most animal cells and essential to the conduction of action potentials in neurons. As noted earlier, the K⁺ concentration gradient that drives the flow of K⁺ ions through open K⁺ channels is generated by the Na⁺K⁺ ATPase. The central role of the Na⁺K⁺ ATPase is reflected in the energy invested in this reaction: about 25% of the total energy consumption of a human at rest.

The steroid derivative ouabain is a potent and specific inhibitor of the Na⁺K⁺ ATPase. Ouabain and another steroid derivative, digitoxigenin, are the active ingredients of digitalis, which has long been used to treat congestive heart failure. Inhibition of the Na⁺K⁺ ATPase by digitalis leads to an increased Na⁺ concentration in cells, activating a Na⁺Ca²⁺ antiporter in cardiac muscle. The increased influx of Ca²⁺ through this antiporter produces elevated cytosolic Ca²⁺, which strengthens the contractions of heart muscle.

The Na⁺K⁺ ATPase has also been investigated for its possible involvement in bipolar disorder pathophysiology (El-Mallakh et al, Biol. Phychiatry, 537:235-244 (1995)). However, this has been an unsettled and controversial subject in the field for many years. Na⁺K⁺ ATPase activity has been variously reported to be increased, decreased, or unchanged in bipolar patients. In 1997, Looney et al conducted a meta-analysis of the available literature on erythrocyte Na⁺K⁺ ATPase activity in bipolar disorders and concluded that it is lower in bipolar patients (Looney et al, Depress. Anxiety, 5:53-65 (1997)). However, the question of exactly how the Na⁺K⁺ ATPase plays a role in bipolar disorders remains unanswered.

Lithium, an alkaline metal that has been used successfully for over fifty years to stabilize mood in bipolar disorders, has been shown to augment Na⁺K⁺ ATPase activity. Recently, the role of lithium in depolarizing the resting membrane potential of neurons has been analyzed (Thiruvengadam, J. Affect. Disord., 65:95-99 (2001); and Thiruvengadam, “Electro-biochemical coupling, excitability of neurons and bipolar disorder, Bipolar Disorder 3 (2001)). Hyperpolarization of membrane potential in leukocytes of bipolar patients and depolarization following the addition of lithium has been observed (El Mallakh et al, J. Affect. Disord., 41:33-37 (1996)). In addition, a significantly smaller increase in Na⁺K⁺ ATPase density after incubation for 72 hours in ethacrynate or lithium has been observed in cells of bipolar patients compared to cells of unaffected individuals (Wood et al, J. Affect. Disord., 21:199-206 (1991)).

El-Mallakh et al measured the transmembrane potential in leukocytes from hospitalized bipolar patients and observed that the transmembrane potential of the bipolar patients was hyperpolarized compared with normal controls and euthymic patients on lithium (El-Mallakh et al, J. Affect. Disord., 41:33-37 (1996)). However, Tamella et al measured the membrane potentials of cultured lymphoblasts and concluded that there was no significant difference in membrane potentials among bipolar patients, their siblings and normal controls (Tamella et al, Psychiatry Res. 59:197-201 (1996)).

In view of the previous studies on the possible involvement of the Na⁺K⁺ ATPase in bipolar disorders, one would not expect Na⁺K⁺ ATPase activity to serve as a reliable basis for diagnosing a bipolar disorder in an individual patient, because measurements of Na⁺K⁺ ATPase activity are highly variable. Similarly, one would not expect transmembrane potential to serve as a reliable basis for diagnosing a bipolar disorder in an individual patient, because measurements of transmembrane potential are highly variable.

Accordingly, despite the existence of treatments for bipolar disorders, ADHD and unipolar disorder, and recent advances in the psychiatric field, there remains a heretofore unmet need for clinical tests to augment the DSM-IV in diagnosing bipolar disorders, ADHD and unipolar disorder.

SUMMARY OF THE INVENTION

The present invention exploits changes that take place in Na⁺K⁺ ATPase regulation in cells of bipolar patients, as compared to cells of normal, unaffected control subjects, to provide a diagnostic assay for a bipolar disorder, such as bipolar I and bipolar II disorders. The present invention provides a reliable diagnostic assay to differentiate cells of bipolar patients from those of normal, unaffected individuals, schizophrenic individuals, ADHD individuals and unipolar (depressive) individuals. The diagnostic assay of the invention may also or instead exploit the similarity of cells from potential bipolar patients to those of people already known to have a bipolar disorder. Thus, the present invention addresses the heretofore unmet need for a clinical test useful in the diagnosis of a bipolar disorder.

The present invention further provides a diagnostic assay useful in differentiating cells from unipolar (depressive) patients from those of normal, unaffected individuals, schizophrenic individuals, ADHD individuals and bipolar individuals. This diagnostic assay may also or instead exploit the similarity of cells from unipolar patients to those of people already known to have unipolar disorder.

The present invention further provides a diagnostic assay useful in differentiating cells from ADHD patients from those of normal, unaffected individuals, schizophrenic individuals, bipolar (I and II) individuals and unipolar individuals. This diagnostic assay may also or instead exploit the similarity of cells from potential ADHD patients to those of people already known to have ADHD.

As shown herein, the membrane potential in cultured cells from bipolar patients is significantly different than the membrane potential in cultured cells from unaffected controls and siblings. For example, the membrane potentials of bipolar lymphoblasts are significantly hyperpolarized when compared with those of siblings and negative controls. The changes in membrane potential reflect changes in Na⁺K⁺ ATPase regulation that occur in cells of patients affected with a bipolar disorder.

In preferred embodiments, a diagnostic assay for a bipolar disorder according to the invention utilizes changes in membrane potential in lymphoblasts or whole blood cells; however, a diagnostic assay for a bipolar disorder according to the invention can also employ changes in membrane potential in lymphocytes, erythrocytes, as well as in other cells.

In additional embodiments, Na⁺K⁺ ATPase activity and therefore membrane potential is manipulated by incubating cells in K⁺-free buffer and/or with one or more compounds that alter the Na⁺ and K⁺ ionic gradients in the cells. Comparisons between cells from bipolar patients and control cells from unaffected individuals (negative controls) incubated under corresponding conditions reveal significant differences that can be quantified and used to diagnose a bipolar disorder. Likewise, comparisons between cells from bipolar patients and cells from other individuals known to have a bipolar disorder (positive controls) incubated under corresponding conditions reveal a lack of a significant difference that can be used to diagnose bipolar disorder.

Unipolar disorder may be diagnosed in a similar manner. For example, comparisons between cells from unipolar patients and control cells from unaffected individuals (negative controls) incubated under corresponding conditions reveal significant differences that can be quantified and used to diagnose unipolar disorder. Likewise, comparisons between cells from unipolar patients and cells from other individuals known to have unipolar disorder incubated under corresponding conditions reveal a lack of a significant difference that can be used to diagnose unipolar disorder.

In a preferred embodiment, a diagnostic assay for unipolar disorder according to the invention utilizes changes in membrane potential in whole blood cells; however, a diagnostic assay for unipolar disorder can also employ changes in membrane potential in lymphoblasts, lymphocytes, erythrocytes, as well as in other cells.

Furthermore, ADHD may be diagnosed in a similar manner. For example, comparisons between cells from ADHD patients and control cells from unaffected individuals (negative controls) incubated under corresponding conditions reveal significant differences that can be quantified and used to diagnose ADHD. Likewise, comparisons between cells from ADHD patients and cells from other individuals known to have ADHD incubated under corresponding conditions reveal a lack of a significant difference that can be used to diagnose ADHD.

In a further preferred embodiment, a diagnostic assay for ADHD according to the invention utilizes changes in membrane potential in whole blood cells; however, a diagnostic assay for ADHD can also employ changes in membrane potential in lymphoblasts, lymphocytes, erythrocytes, as well as in other cells.

The membrane potential of a patient's cells can be ascertained by any conventional method, such as by measuring the fluorescence intensity of a lipophilic fluorescent dye. For example, membrane potentials may be measured using 3,3′-dihexyloxacarbocyanine iodide DiOC₆(3), a cell-permeant, voltage sensitive, green-fluorescent dye, in conjunction with a fluorescence spectrometer.

As used herein, the term bipolar disorder refers to bipolar I disorder and bipolar II disorder. Thus, each of the assays and methods disclosed herein can be performed using either bipolar I or bipolar II cells, and can be used to diagnosis bipolar I or bipolar II disorder.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the membrane potentials of affected (bipolar I) lymphoblasts, non-affected sibling lymphoblasts, and normal lymphoblasts, as indicated by fluorescence intensity of DiOC₆(3) (7 nM), in regular buffer containing K⁺.

FIG. 2 shows the membrane potentials of affected (bipolar I) cells and unaffected cells, as indicated by the fluorescence intensity of DiOC₆(3) in affected cells and the combination of non-affected sibling cells and normal cells.

FIG. 3 shows the fluorescence intensity of DiOC₆(3) in affected (bipolar I) cells and unaffected (sibling and normal) cells relative to the fluorescence intensity of DiOC₆(3) in normal control cell N1.

FIG. 4 shows a comparison of membrane potentials in K⁺-free buffer and in buffer containing K⁺, as indicated by the ratio of fluorescence intensity of DiOC₆(3) in affected (bipolar I) cells and unaffected (sibling and normal) cells in K⁺-free buffer and in K⁺-containing (regular) buffer.

FIG. 5 shows ethacrynate-induced changes in membrane potential, as indicated by the relative ratio of the fluorescence intensity and therefore of the membrane potential of affected (bipolar I) cells and unaffected (sibling and normal) cells in K⁺-free buffer and in K⁺-containing (regular) buffer in the presence or absence of 30 μM ethacrynate.

FIG. 6 shows the effect of ethacrynate on membrane potential, as indicated by the ratio of fluorescence intensity of affected (bipolar I) cells and unaffected (sibling and normal) cells in K⁺-free buffer with or without the addition of 30 μM ethacrynate.

FIG. 7 shows the relative rate of polarization of affected (bipolar I) cells and unaffected (sibling and normal) cells incubated for 30 minutes in K⁺-free buffer and in K⁺-containing (regular) buffer in the presence or absence of 30 μM ethacrynate.

FIG. 8 shows the effect of monensin on membrane potential, as indicated by the ratio of fluorescence intensity of affected (bipolar I) cells and unaffected (sibling and normal) cells in K⁺-free buffer with or without the addition of 10 μM monensin.

FIG. 9 shows the effect of phorbol 12-myristate 13-acetate (PMA) on the rate of repolarization, as indicated by the ratio of repolarization rate of affected (bipolar I) cells and unaffected (sibling and normal) cells in K⁺-free buffer with or without 2 μM PMA.

FIG. 10 shows the effect of PMA on the relative ratio of repolarization rates, as indicated by the ratio of repolarization rate of affected (bipolar I) cells and unaffected (sibling and normal) cells in both K⁺-free buffer and in K⁺-containing (regular) buffer with or without 2 μM PMA.

FIG. 11 shows the effect of lithium on membrane potential, as indicated by the relative ratio of the fluorescence intensity of affected (bipolar I) cells and unaffected (sibling and normal) cells in K⁺-containing (regular) buffer and in K⁺-free buffer in the presence or absence of 20 mM lithium chloride.

FIG. 12 shows the ratio of fluorescence intensities and therefore membrane potentials in K⁺-free buffer containing 30 μM ethacrynate to the fluorescence intensity in K⁺-containing buffer without ethacrynate in an open clinical trial using whole blood samples.

FIG. 13 shows a comparison of ethacrynate and sorbitol in K⁺-free buffer, as used in the open clinical trial using whole blood samples.

FIG. 14 shows the ratio of fluorescence intensities and therefore membrane potentials in K⁺-free buffer containing 30 μM ethacrynate to the fluorescence intensity in K⁺-containing buffer without ethacrynate in a blind clinical trial using whole blood samples from 18 normal controls, 10 schizophrenics, 11 unipolars, and 20 bipolars.

FIG. 15 provides an example of the use of ANOVA in the diagnosis of a representative patient (“Patient A”) as bipolar. The ratio of fluorescence intensities and therefore membrane potentials in K⁺-free buffer containing 30 μM ethacrynate was compared to the fluorescence intensity in K⁺-containing buffer without ethacrynate.

FIG. 16 shows the ratio of fluorescence intensities and therefore membrane potentials in K⁺-free buffer containing 30 μM ethacrynate to the fluorescence intensity in K⁺-containing buffer without ethacrynate in a clinical trial using whole blood samples for bipolar I and bipolar II cells.

FIG. 17 shows the ratio of fluorescence intensities and therefore membrane potentials in K⁺-free buffer containing 30 μM ethacrynate to the fluorescence intensity in K⁺-containing buffer without ethacrynate in a clinical trial using whole blood samples from bipolar I and ADHD patients.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method for diagnosing a patient with a bipolar disorder, such as bipolar I disorder or bipolar II disorder, by comparing the membrane potential of cells of the patient with corresponding control cells of one or more people known not to have a bipolar disorder (negative controls) and/or corresponding bipolar control cells of one or more people known to have a bipolar disorder (positive controls). In experiments described herein, the membrane potentials of lymphoblasts and whole blood cells are ascertained and compared. However, a diagnostic assay according to the present invention can utilize any cell type, such as, but not limited to, erythrocytes, platelets, leukocytes, macrophages, monocytes, dendritic cells, fibroblasts, epidermal cells, mucosal tissue cells, cells in the cerebrospinal fluid, hair cells, etc. Cells present in blood, skin cells, hair cells, or mucosal tissue cells may be more convenient to use because of the ease of harvesting these cell types.

For purposes of a diagnostic assay for a bipolar disorder (such as bipolar I or bipolar II disorder) disclosed herein, “corresponding control cells” means that the cells of the patient are the same type of cells as the control cells of the people known to not have the bipolar disorder. Similarly, for purposes of a diagnostic assay for unipolar disorder disclosed herein, “corresponding control cells” means that the cells of the patient are the same type of cells as the control cells of the people known to not have unipolar disorder. Further, for purposes of a diagnostic assay for ADHD disclosed herein, “corresponding control cells” means that the cells of the patient are the same type of cells as the control cells of the people known to not have ADHD. For example, if the cells of the patient are lymphoblasts, the “corresponding control cells” are lymphoblasts. Likewise, if the cells of the patient are whole blood cells, the “corresponding control cells” are whole blood cells.

For purposes of a diagnostic assay for a bipolar disorder (such as bipolar I or bipolar II disorder) disclosed herein, “corresponding bipolar control cells” means that the cells of the patient are the same type of cells as the bipolar control cells of the people known to have the bipolar disorder. For example, if the cells of the patient are lymphoblasts, the “corresponding bipolar control cells” are lymphoblasts. Likewise, if the cells of the patient are whole blood cells, the “corresponding bipolar control cells” are whole blood cells.

For purposes of a diagnostic assay for unipolar disorder disclosed herein, “corresponding unipolar control cells” means that the cells of the patient are the same type of cells as the unipolar control cells of the people known to have unipolar disorder. For example, if the cells of the patient are whole blood cells, the “corresponding unipolar control cells” are whole blood cells. Likewise, if the cells of the patient are lymphoblasts, the “corresponding unipolar control cells” are lymphoblasts.

For purposes of a diagnostic assay for ADHD disclosed herein, “corresponding ADHD control cells” means that the cells of the patient are the same type of cells as the ADHD control cells of the people known to have ADHD. For example, if the cells of the patient are whole blood cells, the “corresponding ADHD control cells” are whole blood cells. Likewise, if the cells of the patient are lymphoblasts, the “corresponding ADHD control cells” are lymphoblasts.

In a preferred embodiment, a diagnostic assay according to the present invention involves manipulating the membrane potential in cells by either incubating cells with a compound that alters ATPase activity and/or by incubating cells in potassium-free media. The membrane potential of the cells is then ascertained following such treatment.

As indicated above, a cell's membrane potential is the result of the different concentration of ions on either side of the membrane. The activity of the Na⁺K⁺ ATPase pump, which regulates the concentration of Na⁺ and K⁺ to maintain homeostasis, can be altered by a variety of external stimuli, including various chemicals. When the Na⁺ and K⁺ ionic gradients are modulated by some means, the cell regulates the activity of the Na⁺K⁺ ATPase in an effort to return the ionic gradients to normal levels. Some compounds, such as ethacrynate, monensin, and monensin decyl ester, alter the activity of the Na⁺K⁺ ATPase by increasing the intracellular levels of sodium. Other compounds, such as phorbol 12-myristate 13-acetate (PMA), 12-O-tetradecanoylphorbol 13-acetate, phorbol 12-myristate 13-acetate 4-O-methyl ether, phorbol 12,13-dibutyrate (PDBu), phorbol 12,13-didecanoate (PDD), phorbol 12, 13-dinonanoate 20-homovanillate, and other phorbol esters alter the activity of the Na⁺K⁺ ATPase by increasing the density of the Na⁺K⁺ ATPase on the cell surface. Thus, the activity of the Na⁺K⁺ ATPase is affected by its structure, its density, and compounds (both endogenous and exogenous) that affect the structure and density. Genes may play a role also.

Table 1 below shows other examples of compounds that alter the activity of the Na⁺K⁺ ATPase, either indirectly by altering the K⁺ and/or Na⁺ ionic gradients or by acting on the Na⁺K⁺ ATPase itself.

TABLE 1 Chemical K⁺ Na⁺ K⁺ & Na⁺ Na⁺K⁺ ATPase Valinomycin X Monensin X Gramicidin X PCMBS X Veratridine X Ethacrynate X PMA X Dopamine X Catacholamines X Phorbol Esters X Ouabain X Lithium X X X X Valproate X Lamotrigine X Cocaine X Nicotine X R0-31-8220 X Oxymetazoline X Calcineurin X Topiramate X Peptide Hormones X Sorbitol X Diuretics X

In several embodiments, an assay according to the present invention employs such Na⁺K⁺ ATPase-altering compounds to help diagnose patients with a bipolar disorder (such as bipolar I or bipolar II disorder). In other embodiments, an assay according to the present invention employs such Na⁺K⁺ ATPase-altering compounds to help diagnose patients with ADHD or unipolar disorder.

The compounds that are described herein are merely examples of the compounds that could be used to alter Na⁺K⁺ ATPase activity. For example, any compound that increases the density and/or activity of the Na⁺K⁺ ATPase can be used in a diagnostic assay according to the present invention.

In another embodiment, a compound that decreases the density and/or activity of the Na⁺K⁺ ATPase may be used in a diagnostic assay according to the present invention. For example, low concentrations of ouabain may be useful in differentiating bipolar cells from normal cells, and ADHD cells from normal cells, or unipolar cells from normal cells.

Thus, for purposes of this disclosure, “alters Na⁺K⁺ ATPase activity” includes directly altering Na⁺K⁺ ATPase activity by acting directly upon the Na⁺K⁺ ATPase as well as indirectly altering Na⁺K⁺ ATPase activity by, for example, increasing the intracellular sodium concentration. Furthermore, “alters Na⁺K⁺ ATPase activity” includes increasing or decreasing Na⁺K⁺ ATPase activity, although increasing Na⁺K⁺ ATPase activity is preferred.

Potassium uptake in cells of bipolar patients is significantly reduced compared to potassium uptake in cells of normal, unaffected patients. In several embodiments of the present invention, the membrane potential of cells incubated in potassium-free buffer is ascertained with or without incubation with compounds that alter the activity of the Na⁺K⁺ ATPase.

Examples of buffers that may be used in a diagnostic assay according to the present invention, along with their useful pH ranges, are shown in Table 2 below.

TABLE 2 Composition Lower pH Upper pH Glycyl-glycine-piperazine-2HCl—NaOH 4.4 10.8 MES-NaOH—NaCl 5.2 7.1 TRIS-malic acid-NaOH 5.2 8.6 MES-NaOH 5.6 6.8 ADA-NaOH—NaCl 5.6 7.5 ACES-NaOH—NaCl 5.9 7.8 ACES-NaOH—NaCl 5.9 7.8 BES-NaOH—NaCl 6.2 8.1 MOPS-NaOH—NaCl 6.25 8.15 TES-NaOH—NaCl 6.55 8.45 MOPS-KOH 6.6 7.8 HEPES-NaOH—NaCl 6.6 8.5 TRIS-HCl 7.0 9.0 HEPPSO-NaOH 7.4 8.4 BICINE-NaOH—NaCl 7.4 9.3 TAPS-NaOH—NaCl 7.45 9.35 HEPPS (EPPS)-NaOH 7.5 8.7 TRICINE-NaOH 7.6 8.6 BICINE-NaOH 7.7 8.9

Potassium-containing buffers that may be used in a diagnostic assay according to the present invention can be created by adding potassium to the buffers shown in the table above that do not contain potassium. Potassium-containing buffers useful in a diagnostic assay according to the present preferably have a K⁺ concentration in the range of approximately 2 mM to 7 mM, more preferably have a K⁺ concentration of approximately 5 mM, and still more preferably have a K⁺ concentration of 5 mM.

The K⁺-containing buffer used in the examples set forth below is a HEPES buffer to which potassium has also been added (5 mM KCl, 4 mM NaHCO₃, 5 mM HEPES, 134 mM NaCl, 2.3 mM CaCl₂, and 5 mM glucose), and is also referred to as “regular” or “stock” buffer at a pH of 7.4 (range of 7.3 to 7.5). The K⁺-free buffer used in the examples is a HEPES buffer without potassium (4 mM NaHCO₃, 5 mM HEPES, 134 mM NaCl, 2.3 mM CaCl₂, and 5 mM glucose) at a pH of 6.8 (range of 6.6 to 7.0).

The membrane potential of a patient's cells may be ascertained by any conventional method, such as by examining the fluorescence intensity of a potential-sensitive lipophilic fluorescent dye. The membrane potential is directly proportional to the intensity of fluorescence according to the following equation: I=CV, wherein I is the fluorescence intensity of a lipophilic fluorescent dye, V is the voltage or membrane potential, and C is a constant that can vary depending on a number of factors such as, but not limited to, temperature, lamp intensity, number of cells, concentration of the fluorescent dye, incubation time, and lipid composition of cells used. The calibration and determination of the value for C can be a cumbersome and unreliable procedure. Thus, according to the present invention, by using the ratio of the fluorescence intensity (I₁) of one sample of cells to the fluorescence intensity (I₂) of another sample of cells, the constant (C) is canceled out. Such ratio-metric measurements are preferred over absolute measurements.

Examples of potential-sensitive dyes that may be adapted for use in a diagnostic assay according to the present invention, along with their charges and optical responses, are shown below in Table 3 (all available from Molecular Probes Inc., Eugene, Oreg., US).

TABLE 3 Structure Dye (Charge) Optical Response DiOC₂(3) Carbocyanine Slow; fluorescence DiOC₅(3) (cationic) response to DiOC₆(3) depolarization depends on DiSC₃(5) staining concentration DiIC₁(5) and detection method. JC-1 Carbocyanine Slow; fluorescence JC-9 (cationic) emission ratio 585/520 nm increases upon membrane hyperpolarization. Tetramethyl- Rhodamine Slow; used to obtain rhodamine (cationic) unbiased images of methyl and potential-dependent dye ethyl esters distribution. Rhodamine 123 Oxonol V Oxonol Slow; fluorescence Oxonol VI (anionic) decreases upon membrane hyperpolarization. DiBAC₄(3) Oxonol Slow; fluorescence DiBAC₄(5) (anionic) decreases upon membrane DiSBAC₂(3) hyperpolarization. Merocyanine 540 Merocyanine Fast/Slow (biphasic response).

Indo-(DiI), thia-(DiS) and oxa-(DiO) carbocyanines with short alkyl tails (<7 carbon atoms) were among the first potentiometric fluorescent probes developed. These cationic dyes accumulate on hyperpolarized membranes and are translocated into the lipid bilayer. DiOC₆(3) (3,3′-dihexyloxacarbocyanine iodide), a cell-permeant, voltage sensitive, green-fluorescent dye, has been the most widely used carbocyanine dye for membrane potential measurements, followed closely by DiOC₅(3). Thus, in a preferred embodiment of a diagnostic assay according to the present invention, membrane potentials may be measured using DiOC₆(3) in conjunction with a fluorescence spectrometer.

One embodiment of the present invention involves a direct comparison of membrane potentials between cells of a patient in need of a bipolar disorder (such as bipolar I or bipolar II disorder) diagnosis and control cells. See, e.g., Example 2 and FIG. 2. In particular, this embodiment provides a method for diagnosing a bipolar disorder in a patient, comprising:

(a) ascertaining the mean membrane potential of cells of the patient; and one or both of the following steps (b) and (c):

(b) comparing the mean membrane potential of the cells of the patient with the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder, wherein a significant difference between the mean membrane potential of the cells of the patient and the mean membrane potential of corresponding control cells indicates that the patient has the bipolar disorder;

(c) comparing the mean membrane potential of the cells of the patient with the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder, wherein the lack of a significant difference between the mean membrane potential of the cells of the patient and the mean membrane potential of the corresponding bipolar control cells indicates that the patient has the bipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed. The skilled artisan will understand, in view of the additional disclosure herein, that the method can be used to diagnose, separately, each of bipolar I disorder, bipolar II disorder, ADHD and unipolar disorder.

A preferred embodiment of the present invention involves a comparison of the ratios of membrane potentials in K⁺-free buffer to those in K⁺-containing buffer. See, for example, Example 3 and FIG. 4. In particular, this embodiment provides a method for diagnosing a bipolar disorder (such as bipolar I or bipolar II disorder) in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the absence of K⁺ to (ii) the mean membrane potential of cells of the patient incubated in the presence of K⁺; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the absence of K⁺ to (iv) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the presence of K⁺, wherein a significant difference between the patient ratio compared to the control ratio indicates that the patient has the bipolar disorder;

(c) comparing the patient ratio obtained in (a) to a bipolar control ratio, wherein the bipolar control ratio is the ratio of (v) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the absence of K⁺ to (vi) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the presence of K⁺, wherein the lack of a significant difference between the patient ratio and the bipolar control ratio indicates that the patient has the bipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed. The skilled artisan will understand, in view of the additional disclosure herein, that the method can be used to diagnose, separately, each of bipolar I disorder, bipolar II disorder, ADHD and unipolar disorder.

In a preferred embodiment, the significant difference between the patient ratio compared to the control ratio is that the patient ratio is significantly higher than the control ratio.

These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the bipolar control ratio, can be illustrated as follows:

$\begin{matrix} {{patient}\mspace{14mu} {ratio}\text{:}} & \; \\ \frac{{{mean}\mspace{14mu} {m{embrane}}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}}\text{}{{p{atient}}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}{\mspace{11mu} \;}K^{+}}}{{{mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}}{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} K^{+}} & \begin{matrix} (i) \\ \; \\ ({ii}) \end{matrix} \end{matrix}$

compared to:

$\begin{matrix} {{control}\mspace{14mu} {ratio}\text{:}} & \; \\ \frac{{{mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}}{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}}{{{{mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}}\text{}{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} K^{+}}} & \begin{matrix} ({iii}) \\ \; \\ \; \\ ({iv}) \end{matrix} \end{matrix}$

and/or compared to

$\begin{matrix} {{bipolar}\mspace{14mu} {control}\mspace{14mu} {ratio}\text{:}} & \; \\ \frac{{{mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}\mspace{14mu} {bipolar}}\text{}{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}}{{{mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}\mspace{14mu} {bipolar}}{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} {K^{+}.}} & \begin{matrix} \begin{matrix} (v) \\ \; \\ \; \end{matrix} \\ ({vi}) \end{matrix} \end{matrix}$

According to the above, when K⁺ is present, it is preferably present at a concentration of approximately 2-7 mM, more preferably at a concentration of approximately 5 mM, and still more preferably at a concentration of 5 mM.

In another embodiment, the cells of the patient are incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity; and the corresponding control cells, the corresponding bipolar control cells, or both the corresponding control cells and the corresponding bipolar control cells are also incubated in the presence of the compound that alters Na⁺K⁺ ATPase activity.

Yet another preferred embodiment of the present invention involves a comparison of the ratio of membrane potential with and without a Na⁺K⁺ ATPase-altering compound. See, e.g., Example 5 and FIG. 8, and Example 10 and FIG. 15. In particular, this embodiment provides a method for diagnosing a bipolar disorder (such as bipolar I or bipolar II disorder) in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (iv) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein a significantly lower patient ratio compared to the control ratio indicates that the patient has the bipolar disorder;

(c) comparing the patient ratio obtained in (a) to a bipolar control ratio, wherein the bipolar control ratio is the ratio of (v) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (vi) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the patient ratio compared to the bipolar control ratio indicates that the patient has the bipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed. The skilled artisan will understand, in view of the additional disclosure herein, that the method can be used to diagnose, separately, each of bipolar I disorder, bipolar II disorder, ADHD and unipolar disorder.

These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the bipolar control ratio, can be illustrated as follows:

patient  ratio: $\frac{\begin{matrix} {(i){\mspace{11mu} \;}{mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({ii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$

control  ratio: $\frac{\begin{matrix} {({iii}){\mspace{11mu} \;}{mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({iv})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}$

bipolar  control  ratio: $\frac{\begin{matrix} {(v)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{bipolar}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({vi})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {bipolar}\mspace{14mu} {control}\mspace{14mu} {cells}} \\ {{incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{20mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}} \\ {{that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {{activity}.}} \end{matrix}}$

In one embodiment, the cells are incubated in the presence of K⁺, wherein the K⁺ concentration is preferably approximately 2-7 mM, more preferably approximately 5 mM, and still more preferably 5 mM. In another embodiment, the cells are incubated in the absence of K⁺. Preferably, the cells incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity are incubated in the absence of K⁺, and the cells incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity are incubated in the presence of K⁺.

In yet a further embodiment, the present invention provides a method for diagnosing ADHD in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to not have ADHD incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (iv) the mean membrane potential of corresponding control cells of one or more people known to not have ADHD incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein a significantly higher patient ratio compared to the control ratio indicates that the patient has ADHD;

(c) comparing the patient ratio obtained in (a) to an ADHD control ratio, wherein the ADHD control ratio is the ratio of (v) the mean membrane potential of corresponding ADHD control cells of one or more people known to have ADHD incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (vi) the mean membrane potential of corresponding ADHD control cells of one or more people known to have ADHD incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the patient ratio compared to the ADHD control ratio indicates that the patient has ADHD.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed.

These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the ADHD control ratio, can be illustrated as follows:

patient  ratio: $\frac{\begin{matrix} \begin{matrix} {(i)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a} \end{matrix} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({ii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$

control  ratio: $\frac{\begin{matrix} {({iii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({iv})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}$

ADHD  control  ratio: $\frac{\begin{matrix} {(v)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{ADHD}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}} \\ {{of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}} \\ {activity} \end{matrix}}{\begin{matrix} {({vi})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{20mu} {ADHD}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}} \\ {{in}{\mspace{11mu} \;}{the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}} \\ {{Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {{activity}.}} \end{matrix}}$

In one embodiment, the cells are incubated in the presence of K⁺, wherein the K⁺ concentration is preferably approximately 2-7 mM, more preferably approximately 5 mM, and still more preferably 5 mM. In another embodiment, the cells are incubated in the absence of K⁺. Preferably, the cells incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity are incubated in the absence of K⁺, and the cells incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity are incubated in the presence of K⁺.

Yet a further preferred embodiment of the present invention involves a comparison of the ratio of membrane potential with and without a Na⁺K⁺ ATPase-altering compound between two different groups of cells from patients with a disorder, and control cells. See, e.g., Example 13 and FIG. 16, and Example 14 and FIG. 17. In particular, this embodiment provides a method for diagnosing bipolar II disorder in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a bipolar I control ratio, wherein the bipolar I control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to have bipolar I disorder incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (iv) the mean membrane potential of corresponding control cells of one or more people known to have bipolar I disorder incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein a significantly higher patient ratio compared to the bipolar I control ratio indicates that the patient has bipolar II disorder;

(c) comparing the patient ratio obtained in (a) to a bipolar II control ratio, wherein the bipolar II control ratio is the ratio of (v) the mean membrane potential of corresponding control cells of one or more people known to have bipolar II disorder incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (vi) the mean membrane potential of corresponding control cells of one or more people known to have bipolar II disorder incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the patient ratio compared to the bipolar II control ratio indicates that the patient has bipolar II disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed.

These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the bipolar control ratio, can be illustrated as follows:

patient  ratio: $\frac{\begin{matrix} \begin{matrix} {(i)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a} \end{matrix} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} \begin{matrix} {({ii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}{\mspace{11mu} \;}{the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}} \end{matrix} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$

bipolar  I  control  ratio: $\frac{\begin{matrix} {({iii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({iv})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}$

bipolar  II  control  ratio: $\frac{\begin{matrix} \begin{matrix} {(v)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a} \end{matrix} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({vi})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {{activity}.}} \end{matrix}}$

In one embodiment, the cells are incubated in the presence of K⁺, wherein the K⁺ concentration is preferably approximately 2-7 mM, more preferably approximately 5 mM, and still more preferably 5 mM. In another embodiment, the cells are incubated in the absence of K⁺. Preferably, the cells incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity are incubated in the absence of K⁺, and the cells incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity are incubated in the presence of K⁺.

Still a further preferred embodiment of the present invention involves a comparison of the ratio of membrane potential with and without a Na⁺K⁺ ATPase-altering compound between two different groups of cells from patients with a disorder, and control cells. See, e.g., Example 13 and FIG. 16, and Example 14 and FIG. 17. In particular, this embodiment provides a method for diagnosing ADHD in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a bipolar I control ratio, wherein the bipolar I control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to have bipolar I disorder incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (iv) the mean membrane potential of corresponding control cells of one or more people known to have bipolar I disorder incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein a significantly higher patient ratio compared to the bipolar I control ratio indicates that the patient has ADHD;

(c) comparing the patient ratio obtained in (a) to an ADHD control ratio, wherein the ADHD control ratio is the ratio of (v) the mean membrane potential of corresponding control cells of one or more people known to have ADHD incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (vi) the mean membrane potential of corresponding control cells of one or more people known to have ADHD incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the patient ratio compared to the ADHD control ratio indicates that the patient has ADHD.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed.

These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the bipolar control ratio, can be illustrated as follows:

patient  ratio: $\frac{\begin{matrix} \begin{matrix} {(i)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a} \end{matrix} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} \begin{matrix} {({ii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}{\mspace{11mu} \;}{the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}} \end{matrix} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$

bipolar  I  control  ratio: $\frac{\begin{matrix} {({iii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({iv})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}$

ADHD  control  ratio: $\frac{\begin{matrix} {(v)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a}\mspace{11mu}} \\ {\; {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}}} \end{matrix}}{\begin{matrix} {({vi})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}{\mspace{11mu} \;}{the}} \\ {{absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {\mspace{14mu} {{ATPase}\mspace{14mu} {{activity}.}}} \end{matrix}}$

In one embodiment, the cells are incubated in the presence of K⁺, wherein the K⁺ concentration is preferably approximately 2-7 mM, more preferably approximately 5 mM, and still more preferably 5 mM.

In another embodiment, the cells are incubated in the absence of K⁺. Preferably, the cells incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity are incubated in the absence of K⁺, and the cells incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity are incubated in the presence of K⁺.

Still another preferred embodiment of the present invention involves a comparison of the relative ratios of membrane potentials in K⁺-free buffer to those in K⁺-containing buffer with and without a Na⁺K⁺ ATPase-altering compound. See, e.g., Examples 4 and 7 and FIGS. 5 and 11. In particular, this embodiment provides a method for diagnosing a bipolar disorder (such as bipolar I or bipolar II disorder) in a patient, comprising:

(a) obtaining a ratio (patient ratio I) of (i) the mean membrane potential of cells of the patient incubated in the absence of K⁺ and in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity;

(b) obtaining a ratio (patient ratio II) of (iii) the mean membrane potential of cells of the patient incubated in the presence of K⁺ and in the presence of the compound that alters Na⁺K⁺ ATPase activity to (iv) the mean membrane potential of cells of the patient incubated in the presence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity;

(c) obtaining a relative ratio (Relative Patient Ratio) of patient ratio I to patient ratio II; and one or both of the following steps (d) and (e):

(d) comparing the Relative Patient Ratio to a Relative Control Ratio, wherein the Relative Control Ratio is the relative ratio of control ratio I to control ratio II, wherein control ratio I is the ratio of (i′) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the absence of K⁺ and in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii′) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the absence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity, and wherein control ratio II is the ratio of (iii′) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the presence of K⁺ and in the presence of the compound that alters Na⁺K⁺ ATPase activity to (iv′) the mean membrane potential of corresponding control cells of one or more people known to not have the bipolar disorder incubated in the presence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein a significant difference between the Relative Patient Ratio compared to the Relative Control Ratio indicates that the patient has the bipolar disorder;

(e) comparing the Relative Patient Ratio to a Relative Bipolar Control Ratio, wherein the Relative Bipolar Control Ratio is the relative ratio of bipolar control ratio I to bipolar control ratio II, wherein bipolar control ratio I is the ratio of (i″) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the absence of K⁺ and in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii″) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the absence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity, and wherein bipolar control ratio II is the ratio of (iii″) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the presence of K⁺ and in the presence of the compound that alters Na⁺K⁺ ATPase activity to (iv″) the mean membrane potential of corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the presence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the Relative Patient Ratio compared to the Relative Bipolar Control Ratio indicates that the patient has the bipolar disorder.

In one embodiment, steps (a), (b), (c), and (d) are performed. In another embodiment, steps (a), (b), (c), and (e) are performed. In another embodiment, steps (a), (b), (c), (d), and (e) are performed. The skilled artisan will understand, in view of the additional disclosure herein, that the method can be used to diagnose, separately, each of bipolar I disorder, bipolar II disorder, ADHD and unipolar disorder.

In a preferred embodiment, the significant difference between the Relative Patient Ratio and the Relative Control Ratio is that the Relative Patient Ratio is significantly higher than the Relative Control Ratio.

These comparative ratios, wherein the Relative Patient Ratio is compared to the Relative Control Ratio and/or the Relative Bipolar Control Ratio, can be illustrated as follows:

patient  ratio  I: $\frac{\begin{matrix} \begin{matrix} {(i)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {patient}} \\ {{incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}{\mspace{11mu} \;}{the}\mspace{14mu} {presence}} \end{matrix} \\ {{of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({ii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {patient}} \\ {{incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}} \\ {{the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$ patient  ratio  II: $\frac{\begin{matrix} {({iii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}} \\ {activity} \end{matrix}}{\begin{matrix} {({iv})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {patient}} \\ {{incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}} \\ {{of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$

control  ratio  I: $\frac{\begin{matrix} {\left( i^{\prime} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}} \\ {{the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}} \\ {activity} \end{matrix}}{\begin{matrix} {\left( {ii}^{\prime} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}} \\ {{the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}} \\ {activity} \end{matrix}}$ control  ratio  II: $\frac{\begin{matrix} {\left( {iii}^{\prime} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}{\mspace{11mu} \;}{in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}} \\ {{the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}} \\ {activity} \end{matrix}}{\begin{matrix} {{\left( {iv}^{\prime} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}}\mspace{14mu}} \\ {{control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} K^{+}\mspace{14mu} {and}\mspace{14mu} {in}} \\ {{the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}} \\ {activity} \end{matrix}}$

Relative  Bipolar  Control  Ratio: bipolar  control  ratio  I: $\frac{\begin{matrix} {\left( i^{''} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{bipolar}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}} \\ {{and}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {\left( {ii}^{''} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{bipolar}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} K^{+}} \\ {{and}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}$ bipolar  control  ratio  II: $\frac{\begin{matrix} \begin{matrix} \begin{matrix} {\left( {iii}^{''} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{bipolar}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}} \end{matrix} \\ {K^{+}\mspace{14mu} {and}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}} \end{matrix} \\ {{Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} \begin{matrix} \begin{matrix} {{\left( {iv}^{''} \right)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}}\;} \\ {{bipolar}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}} \end{matrix} \\ {K^{+}\mspace{14mu} {and}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}} \end{matrix} \\ {{Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$

Yet another embodiment of the present invention involves a comparison of the repolarization rate between cells of a patient being diagnosed and control cells. See, e.g., Example 4 and FIG. 7. In particular, this embodiment provides a method for diagnosing a bipolar disorder (such as bipolar I or bipolar II disorder) in a patient, comprising:

(a) ascertaining a mean rate of repolarization in cells of the patient incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the mean rate of repolarization ascertained in (a) to the mean rate of repolarization in corresponding control cells of one or more people known to not have the bipolar disorder incubated in the presence of the compound that alters Na⁺K⁺ ATPase activity, wherein a significant difference between the mean rate of repolarization in the cells of the patient compared to the mean rate of repolarization in the corresponding control cells indicates that the patient has the bipolar disorder; (c) comparing the mean rate of repolarization ascertained in (a) to the mean rate of repolarization in corresponding bipolar control cells of one or more people known to have the bipolar disorder incubated in the presence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the mean rate of repolarization in the cells of the patient compared to the mean rate of repolarization in the corresponding bipolar control cells indicates that the patient has the bipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed. The skilled artisan will understand, in view of the additional disclosure herein, that the method can be used to diagnose, separately, each of bipolar I disorder, bipolar II disorder, ADHD and unipolar disorder.

In a preferred embodiment, the significant difference between the mean rate of repolarization in the cells of the patient compared to the mean rate of repolarization in the corresponding control cells is that the mean rate of repolarization in the cells of the patient is significantly higher (e.g. P<0.05) than the mean rate of repolarization in the corresponding control cells.

In one embodiment, the cells are incubated in the presence of K⁺. In another embodiment, the cells are incubated in the absence of K⁺. As used herein, “presence of K⁺” preferably means a K⁺ concentration in the range of approximately 2 mM to 7 mM, preferably approximately 5 mM. For example, the K⁺-containing HEPES buffer used in the examples below has a K⁺ concentration of 5 mM.

In yet another embodiment, the present invention provides a method for diagnosing unipolar disorder in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to not have unipolar disorder incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (iv) the mean membrane potential of corresponding control cells of one or more people known to not have unipolar disorder incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein a significantly higher patient ratio compared to the control ratio indicates that the patient has unipolar disorder;

(c) comparing the patient ratio obtained in (a) to a unipolar control ratio, wherein the unipolar control ratio is the ratio of (v) the mean membrane potential of corresponding unipolar control cells of one or more people known to have unipolar disorder incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity to (vi) the mean membrane potential of corresponding unipolar control cells of one or more people known to have unipolar disorder incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the patient ratio compared to the unipolar control ratio indicates that the patient has unipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed.

These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the unipolar control ratio, can be illustrated as follows:

patient  ratio: $\frac{\begin{matrix} \begin{matrix} {(i)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {presence}\mspace{14mu} {of}\mspace{14mu} a} \end{matrix} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({ii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {cells}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{patient}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}} \\ {{compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {activity}} \end{matrix}}$

control  ratio: $\frac{\begin{matrix} {({iii})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({iv})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}$

unipolar  control  ratio: $\frac{\begin{matrix} {(v)\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}\mspace{14mu} {corresponding}} \\ {{unipolar}\mspace{14mu} {control}\mspace{14mu} {cells}\mspace{14mu} {incubated}\mspace{14mu} {in}\mspace{14mu} {the}} \\ {{presence}\mspace{14mu} {of}\mspace{14mu} a\mspace{14mu} {compound}\mspace{14mu} {that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}} \\ {{ATPase}\mspace{14mu} {activity}} \end{matrix}}{\begin{matrix} {({vi})\mspace{14mu} {mean}\mspace{14mu} {membrane}\mspace{14mu} {potential}\mspace{14mu} {of}} \\ {{corresponding}\mspace{14mu} {unipolar}\mspace{14mu} {control}\mspace{14mu} {cells}} \\ {{incubated}\mspace{14mu} {in}\mspace{14mu} {the}\mspace{14mu} {absence}\mspace{14mu} {of}\mspace{14mu} {the}\mspace{14mu} {compound}} \\ {{that}\mspace{14mu} {alters}\mspace{14mu} {Na}^{+}K^{+}\mspace{14mu} {ATPase}\mspace{14mu} {{activity}.}} \end{matrix}}$

In one embodiment, the cells are incubated in the presence of K⁺, wherein the K⁺ concentration is preferably approximately 2-7 mM, more preferably approximately 5 mM, and still more preferably 5 mM. In another embodiment, the cells are incubated in the absence of K⁺. Preferably, the cells incubated in the presence of a compound that alters Na⁺K⁺ ATPase activity are incubated in the absence of K⁺, and the cells incubated in the absence of the compound that alters Na⁺K⁺ ATPase activity are incubated in the presence of K⁺.

In a preferred embodiment of a diagnostic assay of the present invention, the compound that alters Na⁺K⁺ ATPase activity is a compound selected from the group consisting of: valinomycin, monensin, gramicidin, p-chloromercurybenzenesulfonate (PCMBS), monensin decyl ester, veratridine, ethacrynate, dopamine, a catecholamine, a phorbol ester, ouabain, lithium, valproate, lamotrigine, cocaine, nicotine, the protein kinase C inhibitor R0-31-8220 (Wilkinson et al, Biochem. J. 294:335-337 (1993)), oxymetazoline, calcineurin, topiramate, a peptide hormone, sorbitol, and a diuretic. Preferably, the compound that alters Na⁺K⁺ ATPase activity increases Na⁺K⁺ ATPase activity.

In one embodiment of a diagnostic assay according to the present invention, the compound that alters Na⁺K⁺ ATPase activity is ethacrynate. Preferably, the concentration of ethacrynate is in the range of 1 μM to 100 μM, for example approximately 30 μM, more preferably 30 μM.

In another embodiment of a diagnostic assay according to the present invention, the compound that alters Na⁺K⁺ ATPase activity is monensin. Preferably, the concentration of monensin is in the range of 1 μM to 50 μM, for example approximately 10 μM, more preferably 10 μM.

In another embodiment of a diagnostic assay according to the present invention, the compound that alters Na⁺K⁺ ATPase activity is monensin decyl ester. Preferably, the concentration of monensin decyl ester is in the range of 1 μM to 50 μM, for example approximately 10 μM, more preferably 10 μM.

In another embodiment of a diagnostic assay according to the present invention, the compound that alters Na⁺K⁺ ATPase activity is a phorbol ester. Preferably, the phorbol ester is selected from the group consisting of: phorbol 12-myristate 13-acetate (PMA), 12-O-tetradecanoylphorbol 13-acetate, phorbol 12-myristate 13-acetate 4-O-methyl ether, phorbol 12,13-dibutyrate (PDBu), phorbol 12,13-didecanoate (PDD), and phorbol 12,13-dinonanoate 20-homovanillate. More preferably, the phorbol ester is phorbol 12-myristate 13-acetate (PMA). Preferably, the concentration of phorbol 12-myristate 13-acetate (PMA) is in the range of 0.1 μM to 10 μM, for example approximately 2 μM, more preferably 2 μM.

In another embodiment of a diagnostic assay according to the present invention, the compound that alters Na⁺K⁺ ATPase activity is lithium. Preferably, the concentration of lithium is in the range of 1 μM to 50 μM, for example approximately 20 mM, more preferably 20 mM.

In another preferred embodiment of a diagnostic assay according to the present invention, the mean membrane potential of the cells of the patient is determined by incubating the cells of the patient with a voltage-sensitive fluorescent dye and measuring the fluorescence intensity of the fluorescent dye. Preferably, the dye is a cell-permeant cationic dye. Preferably, the dye is a carbocyanine dye. In a preferred embodiment, the dye is 3,3′-dihexyloxacarbocyanine iodide DiOC₆(3). Preferably, the concentration of dye is in the range of 1 nM to 500 nM, for example approximately 7 nM, more preferably 7 nM.

In another preferred embodiment of a diagnostic assay according to the present invention, the cells of the patient and the corresponding control cells are selected from the group consisting of: lymphoblasts, erythrocytes, platelets, leukocytes, macrophages, monocytes, dendritic cells, fibroblasts, epidermal cells, mucosal tissue cells, cells in the cerebrospinal fluid, hair cells, and cells in whole blood. Preferably, the cells are lymphoblasts or cells in whole blood.

As described more fully in the examples below, the ratio of membrane potentials of bipolar cells in K⁺-free buffer to membrane potentials of bipolar cells in K⁺-containing buffer is significantly different from that of unaffected cells. Cells incubated in ethacrynate (30 μM) show significant differences between bipolar cells and unaffected cells. Cells incubated in monensin (10 μM) and in PMA (2 μM) also show significant differences in specific potentials. In addition to being a mood stabilizer, lithium serves as a medium to distinguish between bipolar cells and unaffected cells.

Further, as shown in a clinical trial using whole blood samples from bipolar, unipolar and schizophrenic patients described more fully below, the ratio of membrane potentials of bipolar cells is significantly different from that of matched control cells (P<0.001). In addition, the ratio of membrane potentials of unipolar cells is significantly different from that of matched control cells (P<0.001).

According to the present invention, when two sample groups are compared for differences for diagnostic purposes, e.g. affected cells and unaffected cells, student's t-test is preferably employed to determine if the two groups are significantly different from each other. As used herein, a “significant difference” (i.e., significantly higher or significantly lower) means that P<0.05. Commercially available statistical software is preferably used for this purpose.

According to the present invention, when more than two sample groups are compared to diagnose whether or not an individual patient is bipolar I, bipolar II, ADHD or unipolar, analysis of variance (ANOVA) test is preferably used. (See Beth Dawson and Robert G. Trapp, Basic and Clinical Biostatistics, Lange Medical Books, McGraw-Hill 3rd Edn.) In a preferred embodiment, an individual patient's cell sample is tested as described herein and six to twelve values are calculated. These patient values are treated as a first sample group and compared with a normal control group (negative control) and a disorder-exhibiting group (positive control) as shown, for example, in Example 10. A diagnosis of one of the disorders of the present invention is made when there is a significant difference (P<0.05) between the normal control group (negative control) and the patient, but there is not a significant difference between the disorder-exhibiting control group (positive control) and the patient.

Although the examples below describe experiments comparing membrane potentials of patients being diagnosed for a particular disorder to groups of controls that were examined contemporaneously, an assay according to the invention preferably compares the mean membrane potential of a patient's cells to predetermined control value or values. Thus, the standard control value(s) do not need to be determined contemporaneously with every patient assay for a disorder, but are preferably pre-determined for later comparisons with patients being diagnosed. Although not contemporaneous, assay conditions between patients and controls are preferably the same. Preferably, control data is pre-determined from various types of corresponding control cells, so that regardless of the type of cells from a patient being tested, control information already exists with which to make a comparison and thus a diagnosis. Furthermore, control data is preferably pre-determined using a control group known not to have any mental illness, in addition to control groups having mental illnesses such as bipolar I or II disorder, ADHD, unipolar disorder, or schizophrenia.

The instant disclosure demonstrates that manipulation of Na⁺K⁺ ATPase activity provides an effective tool for differentiating bipolar I cells from non-bipolar I cells, bipolar II cells from non-bipolar II cells, ADHD cells from non-ADHD cells, and unipolar cells from non-unipolar cells. Novel diagnostic assays for these disorders are thus provided. The specificity and sensitivity of the diagnostic assays described herein compare well with state-of-the-art diagnostic techniques for various other diseases.

As used herein, the term “diagnosis” means that the methods taught herein may be used as one factor in the diagnosis of one of the disorders described herein, or that that the methods taught herein may be used in the absence of other factors in the diagnosis of one of the disorders described herein.

The following examples are provided for illustrative purposes only and are in no way intended to limit the scope of the invention.

EXAMPLES Example 1 Cell Cultures

Three groups of immortalized lymphoblast samples were obtained from the Human Genetic Mutant Cell Repository (Coriell Institute for Medical Research, Camden N.J.). The samples are shown in Table 4 below and included six from affected (bipolar I disorder) patients (A1 through A6), six from their siblings (S1 through S6), and six from unrelated normal control subjects matched by age and sex (N1 through N6).

TABLE 4 Name Coriell Number Age Sex A1 GM05977 26 yr Male A2 GM05999 22 yr Female A3 GM05918 26 yr Female A4 GM06003 16 yr Female A5 GM11051 35 yr Female A6 GM05933 25 yr Female S1 GM05914 23 yr Male S2 GM05901 28 yr Female S3 GM09215 50 yr Male S4 GM05888 18 yr Male S5 GM05901 28 yr Female S6 GM05945 55 yr Female N1 GM06160 25 yr Male N2 GM05408 28 yr Female N3 GM06862 34 yr Female N4 GM06051 26 yr Female N5 GM06861 36 yr Male N6 GM09869 36 yr Male

The cells were grown at 37° C. in RPMI 1640 culture medium (GIBCO, Life Technologies, Gaithersburg, Md., USA) with 15% fetal bovine serum and 1% penicillin.

Example 2 Determination of Membrane Potential

The membrane potentials of the bipolar I cells shown in Table 4 above (as well as in all other experiments, except where indicated) were measured using the following protocol. The cells cultured in the media described above were centrifuged at 210 g for 5 minutes at room temperature, then suspended in 3 ml of K⁺-containing stock buffer (5 mM KCl, 4 mM NaHCO₃, 5 mM HEPES, 134 mM NaCl, 2.3 mM CaCl₂, and 5 mM glucose). The cells were counted and the desired number of cells were again suspended in the K⁺-containing buffer. The membrane potentials were measured using 3,3′-dihexyloxacarbocyanine iodide DiOC₆(3), a cell-permeant, voltage sensitive, green-fluorescent dye (Molecular Probes Inc. Eugene, Oreg. USA). The cells were preincubated for 30 minutes before measurements. The preincubated cell suspension was centrifuged at 210 g for 5 minutes and the cells were resuspended in the K⁺-containing buffer without the dye in the buffer.

A fluorescence spectrometer (F2500 Hitachi, Japan) was used for the measurement of the membrane potential by measuring the fluorescence intensity of DiOC₆(3), which is directly proportional to the membrane potential. The intensity of fluorescence was measured at an excitation wavelength of 488 nm and an output wavelength of 540 nm. The time of recordings varied from 10 seconds to 1500 seconds depending upon the experiment.

Membrane potential was expressed according to fluorescence intensity using the following equation: I=CV, wherein I is the fluorescence intensity of a lipophilic fluorescent dye DiOC₆(3) being only one example of such a dye); V is the voltage or membrane potential; and C is a constant that can vary depending on a number of factors such as, but not limited to, temperature, lamp intensity, number of cells, concentration of the fluorescent dye, incubation time, and lipid composition of cells used. By using the ratio of the fluorescence intensity (I₁) of one sample of cells to the fluorescence intensity (I₂) of another sample of cells, the constant (C) could be canceled out

The measurements of the fluorescence intensity (and thereby membrane potential, per the above equation) indicated that the mean membrane potential of the affected (bipolar I) cells was statistically distinguishable from that of the other cells. FIG. 1 shows box plots of the membrane potentials of lymphoblasts from the three groups tested, namely the affected (bipolar I) cells, non-affected sibling cells, and normal cells, as indicated by the fluorescence intensity of DiOC₆(3) (7 nM) in K⁺-containing (regular) buffer. The differences in the mean values among the groups were greater than would be expected by chance. The mean fluorescence intensity of the affected (bipolar I) cells was significantly lower (P<0.001) by a one-way ANOVA test than that of the sibling cells as well as that of the normal control cells. There was no significant difference between normal cells and sibling cells. The box plots show the 5^(th), 25^(th), 50^(th), 75^(th), and 95^(th) percentile lines. The mean and median lines coincide for the affected cells, but are separated for the other two cell lines. Power of performed test with alpha=0.050:0.991. N=6. Data points=57.

A post-hoc comparison showed a significant difference between affected (bipolar I) cells vs. normal cells and sibling cells, but not between sibling cells and normal cells. Therefore sibling cells and normal cells were combined into a single, “unaffected” category. FIG. 2 shows the membrane potentials of affected (bipolar I) cells and unaffected cells, as indicated by the fluorescence intensity of DiOC₆(3) in affected cells and in the combination of non-affected sibling cells and normal cells. The difference in the mean values of the resulting two groups was greater than would be expected by chance. The mean fluorescence intensity of the affected (bipolar I) cells was significantly lower (P<0.001) than that of the unaffected cells. 95 percent confidence interval for difference of means: −159.577 to −66.090. Power of performed test with alpha=0.050:0.999.

An additional ratio-metric comparison was made by plotting a ratio of fluorescence intensities of the tested cells to that of a cell selected as a standard. FIG. 3 shows the fluorescence intensity of DiOC₆(3) in affected (bipolar I) cells and unaffected (sibling and normal) cells relative to the fluorescence intensity of DiOC₆(3) in the control cell, N1. This ratio-metric procedure accounted for variations in cell count and dye concentration. The difference in the mean values of the resulting two groups was greater than would be expected by chance. The mean relative intensity of the affected (bipolar I) cells was significantly lower (P<0.001) than that of the unaffected cells. t=−5.386 with 54 degrees of freedom. Power of performed test with alpha=0.050:1.000.

The data presented in this example and shown in FIGS. 1-3 indicates that the membrane potential of cells such as lymphoblasts can be used to distinguish groups of patients with bipolar I disorder from groups of unaffected controls.

Example 3 Membrane Potential in K⁺-Free Buffer

Membrane potentials were also measured in K⁺-free buffer to enable comparison with membrane potentials in K⁺-containing buffer. As used herein, K⁺-free buffer contains all of the components of the K⁺-containing buffer, except potassium (4 mM NaHCO₃, 5 mM HEPES, 134 mM NaCl, 2.3 mM CaCl₂, and 5 mM glucose). Constant volumes of samples of each cell line were added to an equal volume of buffer containing an equal volume of dye. K⁺-free buffer as well as K⁺-containing buffer contained an equal volume of cells (and hence an equal number of cells from that culture sample) and an equal concentration of dye. Each variable was constant for each cell line in both buffers, so that the ratio of intensities was a true ratio-metric measurement.

FIG. 4 shows a comparison of membrane potentials in K⁺-free buffer with those in K⁺-containing (regular) buffer, as indicated by fluorescence intensity. 70 nM DiOC₆(3) was added to the cells 30 minutes prior to measuring the membrane potential. The ratio of fluorescence intensity of DiOC₆(3) in K⁺-free buffer to the fluorescence intensity of DiOC₆(3) in K⁺-containing buffer was plotted in the y-axis. The mean value of the ratio of the membrane potential of affected cells was approximately 0.71. In comparison, the mean value of the ratio of the membrane potential of the unaffected cells was approximately 0.51. The ratio of the membrane potential of the unaffected cells was significantly lower than that in affected cells, as indicated by t-test (P=0.020).

The above procedure was also used for the ratio-metric measurements described below.

Example 4 Ethacrynate-Induced Changes in Membrane Potential

Ethacrynate is a loop diuretic prescribed for kidney patients that increases the intracellular sodium concentration and decreases the intracellular potassium concentration. When the intracellular sodium concentration increases, cells correspondingly regulate Na⁺K⁺ ATPase activity to pump the extra sodium out of the cells. Thus, these changes initiate the Na⁺K⁺ ATPase activity to normalize the ionic gradients.

The relative fluorescence intensity ratio of cells in K⁺-free buffer was compared to that of cells in K⁺-containing buffer with or without 30 μM ethacrynate. The cells were incubated with or without ethacrynate (30 μM) for 30 min in K⁺-containing buffer or in K⁺-free buffer. The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. The intensity ratio (membrane potential with ethacrynate/membrane potential without ethacrynate) was compared to the intensity ratio in K⁺-containing buffer and/or in K⁺-free buffer. The relative intensity ratio was obtained by dividing the intensity ratio in K⁺-free buffer by the intensity ratio in K⁺-containing buffer.

A constant sample volume of each cell line was added to an equal volume of each buffer containing an equal volume of dye. Thus, the K⁺-free buffer and the K⁺-containing buffer contained an equal number of cells from each culture sample and an equal concentration of dye.

As shown in FIG. 5, the relative intensity ratio of affected cells was significantly higher than that of unaffected cells by t-test. The mean value of the ratio of the fluorescence intensity of affected cells in K⁺-free buffer to the fluorescence intensity of affected cells in K⁺-containing (regular) buffer was approximately 1.04. The mean value of the ratio of fluorescent intensity of the unaffected cells in K⁺-free buffer to the fluorescence intensity of unaffected cells in K⁺-containing buffer was approximately 0.79. Further, the mean value of the ratio of the affected cells was statistically higher than the mean ratio of unaffected cells (P=0.009).

Similar differences were found in K⁺-containing buffer alone or in K⁺-free buffer alone. The fluorescence intensity of cells incubated in K⁺-free buffer with 30 μM ethacrynate was compared to that of cells incubated in K⁺-free buffer without ethacrynate. The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. As shown in FIG. 6, the intensity ratio (membrane potential of cells incubated with ethacrynate/membrane potential of cells not incubated with ethacrynate) of affected cells was significantly higher than that of unaffected cells by t-test (P=0.032).

As the Na⁺K⁺ ATPase density on the cell surface increases, the intracellular sodium concentration decreases and the membrane potential begins to drop as a result of repolarization of the cell membrane. The rate of drop in membrane potential (repolarization rate) in affected cells incubated for 30 minutes in both K⁺-free buffer and in K⁺-containing (regular) buffer in the presence or absence of 30 μM ethacrynate was compared to that of unaffected cells incubated for 30 minutes in both K⁺-free buffer and in K⁺-containing buffer in the presence or absence of 30 μM ethacrynate. The difference in the median values between the two groups was greater than would be expected by chance. As shown in FIG. 7, the relative rate of repolarization was significantly higher in affected cells compared to that of unaffected cells (P=0.041, as determined by t-test).

Example 5 Monensin-Induced Changes in Membrane Potential

Monensin is an antibiotic ionophore having a 10-fold preference for Na⁺ over K⁺. Monensin increases the intracellular sodium concentration, thus changing the ratio of membrane potentials. The increase in sodium concentration in turn leads to an increase in Na⁺K⁺ ATPase density.

The fluorescence intensity of cells incubated in K⁺-free buffer with 10 μM monensin was compared to that of cells incubated in K⁺-free buffer without monensin. The cells were incubated for 30 minutes. The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. As shown in FIG. 8, the intensity ratio (membrane potential of cells incubated with monensin/membrane potential of cells not incubated with monensin) of affected cells was significantly lower than that of unaffected cells by t-test (P=0.009).

Example 6 PMA-Induced Changes in Membrane Potential

Protein kinase C (PKC) is an essential enzyme involved in the phosphorylation of ATP, which provides energy for the Na⁺K⁺ ATPase. Furthermore, PKC activators such as PMA and inhibitors such as dopamine significantly alter Na⁺K⁺ ATPase density in the presence of monensin.

The rate of drop in membrane potential after incubation with the protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), was compared in affected cells to that of unaffected cells. The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. The rate of drop in membrane potential (repolarization rate) in affected cells was compared to that in unaffected cells in K⁺-free buffer in the presence or absence of 2 μM PMA. The difference in the median values between the two groups was greater than would be expected by chance. The ratio of repolarization rate with PMA divided by the repolarization rate without PMA is shown in FIG. 9. FIG. 9 shows that when the cells were incubated in 2 μM PMA before membrane potential measurements, the repolarization rate in affected cells was significantly different from the repolarization rate in unaffected cells by t-test (P=0.029).

FIG. 10 shows the effect of PMA on the relative ratio of repolarization rates. The rate of drop in membrane potential (repolarization rate) in affected cells incubated for 30 minutes in both K⁺-free buffer and in K⁺-containing (regular) buffer in the presence or absence of 2 μM PMA was compared to that of unaffected cells incubated for 30 minutes in both K⁺-free buffer and in K⁺-containing buffer in the presence or absence of 2 μM PMA. The difference in the median values between the two groups was greater than would be expected by chance. As shown in FIG. 10, the relative ratio of repolarization rates was significantly lower in affected cells compared to than in unaffected cells (P=0.046, as determined by t-test).

Example 7 Lithium-Induced Changes in Membrane Potential

The effect of the addition of lithium, a clinically proven mood stabilizer, on changes in membrane potential in K⁺-free buffer and in K⁺-containing buffer was measured. Cells were incubated with or without lithium chloride (LiCl 20 mM) for 2 hours in K⁺-free buffer or in K⁺-containing buffer.

A constant sample volume of each cell line was added to an equal volume of each buffer containing an equal volume of dye. Thus, the K⁺-free buffer and the K⁺-containing buffer contained an equal number of cells from each culture sample and an equal concentration of dye.

The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. The intensity ratio (membrane potential with lithium/membrane potential without lithium) was compared to the intensity ratio in K⁺-containing buffer and/or in K⁺-free buffer. The relative intensity ratio was obtained by dividing the intensity ratio in K⁺-free buffer by the intensity ratio in K⁺-containing buffer. As shown in FIG. 11, the relative intensity ratio (ratio in K⁺-free buffer with and without lithium/ratio in K⁺-containing (regular) buffer with and without lithium) of affected cells was significantly higher than that of unaffected cells by t-test (P=0.04).

Example 8 Open Clinical Trials

A pilot clinical trial was conducted using blood samples from 12 clinically affected bipolar patients and 11 unaffected controls. The medical histories of the patients were known to the investigator measuring the membrane potentials; therefore, the trials described in this example were open trials. The patients ranged from 19 years to 77 years in age, and included males and females from different ethnic groups. Similarly, the controls ranged from 25 to 67 including males and females from different ethnic groups. The patients were all hospitalized following a confirmed manic episode. During the drawing of samples, all patients were on mood stabilizers, either lithium or valproate.

Because the volume of blood required to collect enough lymphocytes was beyond that permitted by the current protocol, the membrane potential of whole blood cells was determined. The volume of whole blood required was approximately 1 ml. The blood samples were kept on ice until they were stored at 4° C. All of the samples were tested within 48 hours.

Whole blood samples drawn from patients and controls were suspended in K⁺-containing buffer without ethacrynate and in K⁺-free buffer with 30 μM ethacrynate or with 100 mM sorbitol. The fluorescent dye DiOC₆(3) was added to both suspensions and incubated for 30 minutes. The cell suspensions loaded with the dye were centrifuged, drained and resuspended in the respective buffers. The fluorescence intensity was measured for 10 seconds and the ratio of the intensity in K⁺-free buffer to the intensity in K⁺-containing buffer was calculated.

Tables 5 and 6 below present the statistical analysis of the data generated in the trials.

TABLE 5 Clinical Trials (Open Samples) Normality Test: Passed (P > 0.050) Equal Variance Test: Passed (P = 0.523) Group Name N Missing Mean Std Dev SEM Controls 98 0 0.893 0.0485 0.00489 Bipolars 109 0 0.780 0.0521 0.00499 Difference 0.114 t=16.204 with 205 degrees of freedom. (p=<0.001) 95 percent confidence interval for difference of means: 0.0999 to 0.128 The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant difference between the input groups (P=<0.001). Power of performed test with alpha=0.050:1.000

TABLE 6 Descriptive Statistics: Std Std. C.I. Column Size Missing Mean Dev Error of Mean Controls 98 0 0.893 0.0485 0.00489 0.00971 Bipolars 109 0 0.780 0.0521 0.00499 0.00990 Column Range Max Min Median 25% 75% Controls 0.256 1.053 0.797 0.893 0.860 0.925 Bipolars 0.250 0.880 0.629 0.778 0.751 0.817 K-S K-S Sum of Column Skewness Kurtosis Dist. Prob. Sum Squares Controls 0.287 0.141 0.0418 0.863 87.558 78.457 Bipolars −0.425 0.0710 0.0693 0.219 84.988 66.559

Table 5 above indicates that these data passed both the normality test and equal variance test. Table 6 above shows that the mean value is very close to the median value for each of these groups, indicating that the data are normally distributed. The t-test shows significant variance (P<<0.001) among the two groups in open trials, with post-hoc comparisons showing significant differences between controls and bipolar patients.

FIG. 12 graphically depicts the data presented in Tables 5 and 6 above, showing the ratio of fluorescence intensities of the control and bipolar groups in K⁺-free buffer containing 30 μM ethacrynate to the fluorescence intensity in K⁺-containing buffer without ethacrynate. The mean fluorescence intensity ratio of the bipolar samples was significantly lower than that of the control samples by t-test.

FIG. 13 shows that with bipolar patients the results with sorbitol were comparable to the results with ethacrynate. This figure shows a comparison of fluorescence intensity ratios of bipolar cells using ethacrynate and sorbitol in K⁺-free buffer.

Example 9 Blind Clinical Trials

A clinical trial was conducted using blood samples from the following four groups: schizophrenic, bipolar, and unipolar patients, as well as controls. The medical histories of these patients were unknown to the investigator measuring the membrane potentials; therefore, the trials described in this example were blind trials. The sample size was determined to be 5 with a power of 0.9, an alpha of 0.05, a difference in mean of 0.08, and a standard deviation of 0.03. However, more than 10 samples for each category were tested for a total sample size of 59. If a patient matched a diagnosis, structured clinical interviews according to DSM-IV guidelines were performed.

Whole blood samples drawn from patients and controls were suspended both in K⁺-containing buffer and in K⁺-free buffer with 30 μM ethacrynate or with 100 μM sorbitol. The fluorescent dye DiOC₆(3) was added to both suspensions and incubated for 30 minutes. The cell suspensions loaded with the dye were centrifuged, drained and resuspended in the respective buffers. The fluorescence intensity was measured for 10 seconds and the ratio of the intensity in K⁺-free buffer to the intensity in K⁺-containing buffer was calculated.

Tables 7 and 8 below present the statistical analysis of the four groups.

TABLE 7 One Way Analysis of Variance SUMMARY OF BLIND TRIALS Normality Test: Passed (P > 0.050) Equal Variance Test: Failed (P = <0.001) Test execution ended by user request, ANOVA on Ranks begun Kruskal-Wallis One Way Analysis of Variance on Ranks Group N Missing Median 25% 75% Controls 173 0 0.850 0.829 0.869 Schizophr. 78 0 0.863 0.838 0.895 Bipolars 178 0 0.773 0.752 0.790 Unipolars 72 0 0.901 0.863 0.934 H = 351.025 with 3 degrees of freedom. (P = <0.001) The differences in the median values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = <0.001) To isolate the group or groups that differ from the others use a multiple comparison procedure. All Pairwise Multiple Comparison Procedures (Dunn's Method): Comparison Diff of Ranks Q P < 0.05 Unipolars vs Bipolars 308.546 15.260 Yes Unipolars vs Controls 95.297 4.694 Yes Unipolars vs Schizophr. 52.263 2.209 No Schizophr. vs Bipolars 256.283 13.037 Yes Schizophr. vs Controls 43.034 2.180 No Controls vs Bipolars 213.249 13.797 Yes

TABLE 8 Descriptive Statistics: SUMMARY OF BLIND TESTS Column Size Missing Mean Std Dev Std. Error C.I. of Mean Controls 173 0 0.850 0.0290 0.00220 0.00435 Schizophr. 78 0 0.870 0.0428 0.00484 0.00964 Bipolars 178 0 0.768 0.0300 0.00225 0.00444 Unipolars 72 0 0.898 0.0486 0.00573 0.0114 Column Range Max Min Median 25% 75% Controls 0.180 0.929 0.749 0.850 0.829 0.869 Schizophr. 0.200 0.994 0.794 0.863 0.838 0.895 Bipolars 0.164 0.830 0.667 0.773 0.752 0.790 Unipolars 0.199 1.004 0.805 0.901 0.863 0.934 K-S K-S Sum of Column Skewness Kurtosis Dist. Prob. Sum Squares Controls 0.0895 0.607 0.0400 0.661 147.073 125.176 Schizophr. 0.682 0.132 0.0827 0.203 67.885 59.222 Bipolars −0.601 0.187 0.0742 0.018 136.709 105.156 Unipolars 0.0506 −0.849 0.0762 0.362 64.645 58.210

FIG. 14 graphically depicts the data presented in Tables 7 and 8 above, showing a summary of these blind test results using whole blood samples. The figure shows the ratio of fluorescence intensities of the sample groups in K⁺-free buffer containing 30 μM ethacrynate to the fluorescence intensity in K⁺-containing buffer without ethacrynate. The coefficient of variation ranged from 3.5 to 4.5 in all these tests. There were no significant differences among the normals and schizophrenics. However, blood samples from bipolar patients were significantly different from the other three groups, as determined by ANOVA (P<<0.001). In particular, the fluorescence intensity ratio of the bipolar samples was significantly lower than that of the other three groups. Furthermore, there was a significant difference between normals and unipolar patients, as determined by ANOVA. In particular, the fluorescence intensity ratio of the unipolar samples was significantly higher than that of the other three groups. These results are therefore useful in diagnosing unipolar (depressive) patients as well.

Example 10 Diagnosis of an Individual Patient as Bipolar

An individual patient's cell sample was tested as described herein and six to twelve ratios were calculated. These values were treated as a group and compared with a normal control group (negative control) and a bipolar group (positive control).

Tables 9 and 10 below present the statistics and the procedure employed for “Patient A.” At the bottom of Table 9 there is pair wise comparison of these groups.

TABLE 9 One Way Analysis of Variance Normality Test: Passed (P > 0.050) Equal Variance Test: Passed (P = 0.050) Group Name N Missing Mean Std Dev SEM Controls 173 0 0.850 0.0290 0.00220 Bipolars 178 0 0.768 0.0300 0.00225 Patient A 12 0 0.766 0.0125 0.00359 Source of Variation DF SS MS F P Between Groups 2 0.613 0.306 360.229 <0.001 Residual 360 0.306 0.000850 Total 362 0.919 The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = <0.001). Power of performed test with alpha = 0.050:1.000 All Pairwise Multiple Comparison Procedures (Holm-Sidak method): Overall significance level = 0.05 Comparisons for factor: Diff of Critical Comparison Means t Unadjusted P Level Significant? Controls vs 0.0821 26.372 0.000 0.017 Yes Bipolars Controls vs 0.0844 9.699 0.000 0.025 Yes Patient A Bipolars vs 0.00233 0.268 0.789 0.050 No Patient A

TABLE 10 Descriptive Statistics: Column Size Missing Mean Std Dev Std. Error C.I. of Mean Controls 173 0 0.850 0.0290 0.00220 0.00435 Bipolars 178 0 0.768 0.0300 0.00225 0.00444 Patient A 12 0 0.766 0.0125 0.00359 0.00791 Column Range Max Min Median 25% 75% Controls 0.180 0.929 0.749 0.850 0.829 0.869 Bipolars 0.164 0.830 0.667 0.773 0.752 0.790 Patient A 0.0394 0.787 0.748 0.763 0.755 0.777 K-S Sum of Column Skewness Kurtosis K-S Dist. Prob. Sum Squares Controls 0.0895 0.607 0.0400 0.661 147.073 125.176 Bipolars −0.601 0.187 0.0742 0.018 136.709 105.156 Patient A 0.347 −1.092 0.138 0.665 9.188 7.037

As shown in Tables 9 and 10 above, there was a significant difference between controls and the patient. However, there was no significant difference between the patient and the bipolar group. From this, Patient A was diagnosed as bipolar.

FIG. 15 graphically depicts an example of the use of ANOVA in the diagnosis of Patient A as bipolar. The ratio of fluorescence intensities and therefore membrane potentials in K⁺-free buffer containing 30 μM ethacrynate was compared to the fluorescence intensity in K⁺-containing buffer without ethacrynate. The fluorescence intensity ratio of the patient's cell sample was significantly lower than that of the controls, but was not significantly different from that of the bipolars.

Example 11 Diagnosis of an Individual Patient as Unipolar

An individual patient's cell sample is tested as described herein and six to twelve ratios are calculated. These values are treated as a group and compared with a normal control group (negative control) and a unipolar group (positive control), in a manner similar to that described above in Example 10 for diagnosing an individual patient as bipolar.

The ratio of fluorescence intensities and therefore membrane potentials in K⁺-free buffer containing 30 μM ethacrynate are compared to the fluorescence intensity in K⁺-containing buffer without ethacrynate.

A patient is diagnosed as unipolar when there is a significant difference between controls and the patient (i.e., the fluorescence intensity ratio of the patient's cell sample is significantly higher than that of the controls) and/or there is no significant difference between the unipolar group and the patient. ANOVA is used in the diagnosis of a patient as unipolar.

Example 12 Specificity and Sensitivity of the Diagnostic Whole Blood Tests

Specificity is the ability to identify those who do not have the disease (Dawson et al, “Basic and Clinical Biostatistics”, Third Edition, Lange Medical Books/McGraw-Hill, New York (2002)). As shown below in Table 11, the specificity in identifying controls was 100% in the blind trials described above in Example 9. Out of a control population (those with no known mental illness) of 18, all were diagnosed as negative for a bipolar disorder. The specificity for the overall non-bipolar (including schizophrenics and unipolars) population of 39 was 85% (33 out of 39) in the above-described blind trials. Among the schizophrenic patients, the test diagnosed 8 out of 10 correctly, indicating a specificity of 80% in the above-described blind trials. The specificity for the unipolar patients was 64% (seven out of eleven) in the above-described blind trials.

Sensitivity is defined as a test's ability to detect a disease among patients who actually have the disease (Dawson et al, supra). In the above-described blind trials, among the population of 20 bipolar patients (which were determined according to examination using the DSM IV), 14 were true positives. Hence the sensitivity of the test was 70%. However, doubts about the accuracy of DSM IV-based diagnoses of a bipolar disorder make the estimate of sensitivity unclear.

Consideration was given to whether patients on lithium and patients with diabetes during the blood draw could generate false diagnoses. Of the true positives, one patient was on lithium and 2 were diabetic. Of the false negatives, 2 patients were on lithium and 4 were diabetic. Lithium and diabetes did not have an effect on false positives and true negatives. Thus, lithium and diabetes did not appear to play a role on these tests.

TABLE 11 Summary Of Blind Tests For Bipolar Disorder Total samples tested: 59 Total positives: 20 Total negatives: 39 Diagnostic Blind Test Results Total negatives 39 True negatives 33 Specificity 85% Total controls 18 True controls 18 Specificity 100%  Total schizophrenics 10 True schizophrenics  8 Specificity 80% Total unipolars 11 True unipolars  7 Specificity 64% Total bipolars 20 True positives 14 Sensitivity 70%

While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof. All such obvious and foreseeable changes and modifications are intended to be encompassed by the following claims.

Example 13 Bipolar I and Bipolar II

Cells from control, bipolar I and bipolar II individuals were compared amongst each other as described herein. Whole blood samples drawn from patients and controls and aliquots were suspended either in K⁺-containing buffer without ethacrynate, or in K⁺-free buffer with 30 μM ethacrynate. The fluorescent dye DiOC₆(3) was added to the suspensions and incubated for 30 minutes. The cell suspensions loaded with the dye were centrifuged, drained and resuspended in the respective buffers. The fluorescence intensity was measured for 10 seconds and the ratio of the intensity in K⁺-free buffer to the intensity in K⁺-containing buffer was calculated. Plate Reader (PerkinsElmer Victor V) was used for intensity measurements). The results are shown in FIG. 16 and Table 12.

As seen in Table 12, there is a significant difference between bipolar I and bipolar II with a P<0.001. The difference in mean values is also shown in Table 12. These results indicate that this blood test is valid for bipolar I and bipolar II disorders.

TABLE 12 One Way Analysis of Variance Data source: Data 1 in Notebook 1 Normality Test: Failed (P = 0.002) Test execution ended by user request, ANOVA on Ranks begun Kruskal-Wallis One Way Analysis of Variance on Ranks Data source: Data 1 in Notebook 1 Group N Missing Median 25% 75% Negative 123 0 0.676 0.662 0.696 BPD I 55 0 0.606 0.590 0.616 BPD II 20 0 0.648 0.644 0.653 H = 136.763 with 2 degrees of freedom. (P = <0.001) The differences in the median values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = <0.001) To isolate the group or groups that differ from the others use a multiple comparison procedure. All Pairwise Multiple Comparison Procedures (Dunn's Method): Comparison Diff of Ranks Q P < 0.05 Negative vs BPD I 107.041 11.516 Yes Negative vs BPD II 60.550 4.383 Yes BPD II vs BPD I 46.491 3.107 Yes

Example 14 ADHD

Cells from control, bipolar I and ADHD individuals were compared amongst each other as described herein. Whole blood samples drawn from patients and controls and aliquots were suspended either in K⁺-containing buffer without ethacrynate, or in K⁺-free buffer with 30 μM ethacrynate. The fluorescent dye DiOC₆(3) was added to the suspensions and incubated for 30 minutes. The cell suspensions loaded with the dye were centrifuged, drained and resuspended in the respective buffers. The fluorescence intensity was measured for 10 seconds and the ratio of the intensity in K⁺-free buffer to the intensity in K⁺-containing buffer was calculated. Plate Reader (PerkinsElmer Victor V) was used for intensity measurements). The results shown in FIG. 17 and Table 13.

FIG. 17 shows the box plots for 18 patients diagnosed with ADHD and 54 bipolar I patients. There is a statistically significant difference between these two illnesses with a P<0.001 as shown in Table 13. The difference in mean values is statistically significant as shown Table 13.

TABLE 13 One Way Analysis of Variance Data source: Data 1 in Notebook 1 Normality Test: Passed (P > 0.050) Equal Variance Test: Failed (P = <0.001) Test execution ended by user request, ANOVA on Ranks begun Kruskal-Wallis One Way Analysis of Variance on Ranks Data source: Data 1 in Notebook 1 Group N Missing Median 25% 75% Negative 123 0 0.676 0.662 0.696 BPD I 55 0 0.606 0.590 0.616 ADHD 95 0 0.808 0.771 0.839 H = 230.158 with 2 degrees of freedom. (P = <0.001) The differences in the median values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = <0.001) To isolate the group or groups that differ from the others use a multiple comparison procedure. All Pairwise Multiple Comparison Procedures (Dunn's Method) Comparison Diff of Ranks Q P < 0.0 ADHD vs BPD I 196.936 14.722 Yes ADHD vs Negative 107.396 9.959 Yes Negative vs BPD I 89.539 6.992 Yes 

1. (canceled)
 2. A method for diagnosing attention-deficit/hyperactivity disorder (ADHD) in a human patient, comprising: (a) obtaining a ratio of (i) the mean membrane potential of cells of a test human patient incubated in vitro in the presence of a compound that alters Na⁺K⁺ ATPase activity, but in the absence of K⁺, to (ii) the mean membrane potential of cells of the test human patient incubated in vitro in the absence of the compound that alters Na⁺K⁺ ATPase activity, but in the presence of K⁺; and at least one of the following steps (b) or (b′): (b) comparing the ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more humans known to not have ADHD incubated in vitro in the presence of a compound that alters Na⁺K⁺ ATPase activity, but in the absence of K⁺, to (iv) the mean membrane potential of corresponding control cells of one or more humans known to not have ADHD incubated in vitro in the absence of the compound that alters Na⁺K⁺ ATPase activity, but in the presence of K⁺, wherein when the ratio obtained in (a) is significantly higher than the control ratio obtained in (b), said test human patient is diagnosed as having ADHD; (b′) comparing the ratio obtained in (a) to a ADHD control ratio, wherein the ADHD control ratio is the ratio of (v) the mean membrane potential of corresponding ADHD control cells of one or more humans known to have ADHD incubated in vitro in the presence of a compound that alters Na⁺K⁺ ATPase activity, but in the absence of K⁺, to (vi) the mean membrane potential of corresponding ADHD control cells of one or more humans known to have ADHD incubated in vitro in the absence of the compound that alters Na⁺K⁺ ATPase activity, but in the presence of K⁺, wherein when the ratio obtained in (a) is not significantly different than the ADHD control ratio obtained in (b′), said test human patient is diagnosed as having ADHD, wherein each mean membrane potential is determined by incubating the cells in vitro in buffer comprising a potential-sensitive dye, resuspending the cells in potential-sensitive dye free-buffer, and measuring cell fluorescence.
 3. (canceled)
 4. A method for diagnosing ADHD in a human patient, comprising: (a) obtaining a ratio of (i) the mean membrane potential of cells of a human test patient incubated in vitro in the presence of a compound that alters Na⁺K⁺ ATPase activity, but in the absence of K⁺, to (ii) the mean membrane potential of cells of the test human patient incubated in vitro in the absence of the compound that alters Na⁺K⁺ ATPase activity, but in the presence of K⁺; and at least one of the following steps (b) or (b′): (b) comparing the ratio obtained in (a) to a bipolar I control ratio, wherein the bipolar I control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more humans known to have bipolar I disorder incubated in vitro in the presence of a compound that alters Na⁺K⁺ ATPase activity, but in the absence of K⁺, to (iv) the mean membrane potential of corresponding control cells of one or more humans known to have bipolar I disorder incubated in vitro in the absence of the compound that alters Na⁺K⁺ ATPase activity, but in the presence of K⁺, wherein when the ratio obtained in (a) is significantly higher than the bipolar I control ratio obtained in (b), said test human patient is diagnosed as having ADHD; (b′) comparing the ratio obtained in (a) to an ADHD control ratio, wherein the ADHD control ratio is the ratio of (v) the mean membrane potential of corresponding control cells of one or more humans known to have ADHD incubated in vitro in the presence of a compound that alters Na⁺K⁺ ATPase activity, but in the absence of K⁺, to (vi) the mean membrane potential of corresponding control cells of one or more humans known to have ADHD incubated in vitro in the absence of the compound that alters Na⁺K⁺ ATPase activity, but in the presence of K⁺, wherein when the ratio obtained in (a) is not significantly different than the ADHD control ratio obtained in (b′), said test human patient is diagnosed as having ADHD, wherein each mean membrane potential is determined by incubating the cells in vitro in buffer comprising a potential-sensitive dye, resuspending the cells in potential-sensitive dye free-buffer, and measuring cell fluorescence.
 5. The method according to claim 2 or 4, wherein steps (a) and (b) are performed. 6-9. (canceled)
 10. The method according to claim 2 or 4, wherein K⁺ is present at a concentration of 2-7 mM. 11-12. (canceled)
 13. The method according to any one of claim 2 or 4, wherein the compound that alters Na⁺K⁺ ATPase activity is selected from the group consisting of: valinomycin, monensin, monensin decyl ester, p-chloromercurybenzenesulfonate (PCMBS), veratridine, ethacrynate, dopamine, a catecholamine, a phorbol ester, ouabain, lithium, valproate, lamotrigine, cocaine, nicotine, R0-31-8220, oxymetazoline, calcineurin, topiramate, a peptide hormone, sorbitol, and a diuretic. 14-18. (canceled)
 19. The method according to any one of claim 2 or 4, wherein the compound that alters Na⁺K⁺ ATPase activity is a phorbol ester.
 20. The method according to claim 19, wherein the phorbol ester is selected from the group consisting of: phorbol 12-myristate 13-acetate (PMA), 12-O-tetradecanoylphorbol 13-acetate, phorbol 12-myristate 13-acetate 4-O-methyl ether, phorbol 12,13-dibutyrate (PDBu), phorbol 12,13-didecanoate (PDD), and phorbol 12,13-dinonanoate 20-homovanillate. 21-28. (canceled)
 29. The method according to any one of claim 2 or 4, wherein each of the cells used therein is selected from the group consisting of: lymphoblasts, erythrocytes, platelets, leukocytes, macrophages, monocytes, dendritic cells, fibroblasts, epidermal cells, mucosal tissue cells, cells of cerebrospinal fluid, hair cells, and cells of whole blood. 30-31. (canceled) 